CTNNB1 exon 3 mutations in metastatic solid pseudopapillary neoplasm of the pancreas
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Andrew M Fleming und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, beta Catenin, Exons. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives Solid pseudopapillary neoplasm (SPN) of the pancreas demonstrates an indolent disease course; however, some patients present with a “malignant” phenotype, including distant metastases resistant to chemotherapy. This analysis identifies molecular drivers of metastatic SPN using the world's largest clinicogenomics database.
Methods
The American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange was queried for primary and metastatic SPN samples. Sample‐level genomic alterations were compared. A pan‐pancreatic cancer analysis assessed relevant mutations among all metastatic pancreatic malignancies.
Results
Among 28 SPN samples identified ( n = 17 primary, n = 11 metastatic), the most commonly mutated gene was CTNNB1, (24/28 samples; 85.7%). Most mutations were missense (21/24; 87.5%) or in‐frame deletions (3/24; 12.5%). The most common CTNNB1 mutations in primary SPN were exon 3 S37F/C missense mutations (6/16 profiled patients, 37.5%), contrasting exon 3 D32N/Y/H missense mutations in metastatic samples (6/11 profiled patients, 54.5%). Metastatic SPN had higher rates of CTNNB1 mutations than metastases from pancreatic ductal adenocarcinoma (72.7% vs. 1.1%; q < 0.0001), pancreatic neuroendocrine tumor (72.7% vs. 2.5%; q < 0.0001), and pancreatic acinar cell carcinoma (72.7% vs. 11.5%; q = 0.0254).
Conclusions
Missense mutations along exon 3 of CTNNB1 predominate metastatic SPN, differentiating these patients from those with metastases from analogous pancreatic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Division of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Surgery, Augusta University Medical Center, Augusta, Georgia, USA.
- Department of Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
- Department of Surgery, University of Miami Health System, Miami, Florida, USA.
Zitieren
APA
Fleming, A. M., Gehle, D. B., Freitas, J. P., Hendrick, L. E., Yakoub, D., Abdelhafeez, H., Nezakatgoo, N., Deneve, J. L., Langham, M. R., Glazer, E. S., Shibata, D., Merchant, N. B., Dickson, P. V., & Murphy, A. J. (2024). CTNNB1 exon 3 mutations in metastatic solid pseudopapillary neoplasm of the pancreas. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27808
Vancouver
Fleming AM, Gehle DB, Freitas JP, Hendrick LE, Yakoub D, Abdelhafeez H, et al. CTNNB1 exon 3 mutations in metastatic solid pseudopapillary neoplasm of the pancreas. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27808
BibTeX
@article{Fleming2024,
author = {Fleming, Andrew M and Gehle, Daniel B and Freitas, Julia Pedo and Hendrick, Leah E and Yakoub, Danny and Abdelhafeez, Hafeez and Nezakatgoo, Nosratollah and Deneve, Jeremiah L and Langham, Max R and Glazer, Evan S and Shibata, David and Merchant, Nipun B and Dickson, Paxton V and Murphy, Andrew J},
title = {CTNNB1 exon 3 mutations in metastatic solid pseudopapillary neoplasm of the pancreas},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27808}
}
EUVIMED